Zimmer Biomet Holdings announced the appointment of Kevin Thornal as Group President, Global Businesses and the Americas. Reporting to Chairman-Elect, President and CEO Ivan Tornos, Thornal will join the Company on July 1, 2025 to oversee the Americas commercial organization and lead business strategy and execution for its global Knees, Hips, S.E.T. and Data, Technology, and Enabling Solutions units.
“Kevin is an incredible addition to our leadership team at an exciting time for our Company,” said Tornos. “He brings a bold desire to win and a demonstrated track record of delivering consistently strong growth, driving commercial excellence and building high-performing teams. I am confident his breadth and depth of experience will serve us well as we work together to elevate our U.S. performance and commercial execution, deliver value for all stakeholders, and advance our Mission of alleviating pain and improving the quality of life for people around the world.”
Thornal is a seasoned leader with more than 20 years of experience in the medical technology, orthopedics and diagnostics industries. Prior to his most recent role as CEO and President of Nevro Corp., Thornal spent nine years at Hologic, Inc., where he held several leadership positions of increasing responsibility including Group President of Global Diagnostic Solutions. At Hologic, Inc., Thornal led the Diagnostic Solutions division during the COVID-19 pandemic and oversaw global teams in R&D, operations and commercial as the company rapidly launched new products, consistently delivered double-digit growth and expanded its international footprint.
Thornal also has a deep understanding of the orthopedics industry, developed during his tenure at Stryker Corp., where he held roles of increasing responsibility in sales, marketing and corporate business development from 2004 to 2014. As head of North American sales for Stryker’s Interventional Spine business, Thornal led his team to achieve sustained double-digit growth.
“I could not be more excited to return to orthopedics and join Zimmer Biomet on the journey to becoming the boldest company in medical technology,” said Thornal. “There’s a tremendous opportunity to address key unmet needs in musculoskeletal health by helping more customers and patients access the Company’s robust new product pipeline. I look forward to working with this talented team, contributing to Zimmer Biomet’s culture of collaboration and innovation and delivering meaningful outcomes for patients and customers around the world.”
MB Bureau
